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The aims of this pilot study were to determine whether needle and open biopsies from osteosarcoma (OS) provide sufficient quality
of mRNA for cDNA array analyses to gain insights into the expression profile of OS. A total of 22 samples collected from OS were
used for array analyses. A primary cell culture was also established from one of the OS biopsies. Total RNA was extracted and probes
were generated for cDNA arrays. cDNA probes were made for all the 22 samples. Two of these samples were needle core bone
biopsies. Statistical analysis confirmed the reliability of array data obtained in 16 of the 22 samples. Known genes involved in bone
metabolism and osteosarcoma were identified as highly expressed, and the putative new marker Ezrin was also identified.
Confirmatory immunohistochemical staining using the Ezrin antibody was performed in a selection of samples.
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Osteosarcoma (OS) is the commonest high-grade primary bone
malignancy. It characteristically affects the long bones of teenagers
with a peak age incidence between 13 and 16 years, but may also
occur with a lower incidence throughout adulthood. However, it
remains a rare tumour and only 130 and 1000 new cases are
diagnosed each year in the UK and US, respectively (Dorfman &
Czerniak, 1995; Whelan and Cannon, 2002).
Osteosarcoma may be suspected on the basis of characteristic
clinical and radiological features. The diagnosis is generally
established by core needle biopsy after which preoperative
combination chemotherapy is followed by surgery, either with
limb salvage or less commonly nowadays by amputation.
Chemotherapy is continued postoperatively for up to 6 months.
Before the introduction of cytotoxic treatment, less than 20% of
patients with OS were cured (Stiller and Bunch, 1990). Although
adjuvant and neoadjuvant cytotoxic treatment and more refined
surgical procedures have increased 5-year survival to over 60%,
treatment remains crude, invasive and highly toxic for the majority
of patients (Ferguson & Goorin, 2001).
Since the 1970s, histological response to presurgical chemother-
apy has provided the most consistent and reliable prognostic
indicator: those patients with localised disease whose tumours
have undergone more than 90% necrosis have a 5-year survival in
the region of 70%, while for those in whom the response falls short
of 90%, survival rarely exceeds 40–50% (Davis et al, 1994).
Alteration of chemotherapy postoperatively for those patients with
a poor response has as yet not been demonstrated to improve
outcome, and the relative rarity of OS has stifled the development
and testing of novel agents for this disease, resulting in little
progress to improve survival within the last decade.
Currently, most tumours are categorised on the basis of
morphology. The identification of markers that distinguish
subtypes of tumours and which may have prognostic and
therapeutic implications is urgently needed. Gene expression
microarrays (GEM) with bioinformatics analysis can be used to
identify the molecular fingerprint (or signature) of an individual
patient’s tumour, and simple hierarchical clustering has already
led to the identification of new classes of cancer that transcend the
distinctions based on morphology and immunohistochemistry
(DeRisi et al, 1996; Perou et al, 1999; Alizadeh et al, 2000; Perou
et al, 2000). More advanced computational methodologies includ-
ing supervised learning (Shipp et al, 2002) and artificial neural
networks have also been used to define subtypes of breast (Seker
et al, 2002) and colorectal cancer (Selaru et al, 2002).
Osteosarcoma may be particularly amenable to GEM analysis, as
samples are routinely obtained before and after chemotherapy. The
gene expression profile prior to therapy may thus be correlated
with histological response after neoadjuvant treatment. A potential
drawback, however, is that the small core biopsy samples obtained
for diagnostic purposes may contain a proportion of calcified bone
and therefore be unsuitable for the generation of cDNA probes for
array hybridisation technologies.
The aims of this study were to determine if sufficient high-
quality mRNA could be obtained from both needle core and open
biopsy OS samples from which to generate cDNA probes to obtain
array data.
MATERIALS AND METHODS
Patient and clinical tissue
In total, 22 fresh frozen high-grade OS specimens were obtained
from surplus material used for diagnostic purposes. Clinical
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ycharacteristics of 16 patients included in the analysis are
summarised in (Table 1). Ethical Committee approval was
obtained from The Royal National Orthopaedic Hospital NHS
Trust for this study.
Cell culture
From one of the samples (met-738), primary cells were cultured for
array analysis (met-c738). The sample was placed in 165iu
collagenase (Collagenase type 2 GIBCOt Invitrogen Corporation,
Daisley, UK) to disaggregate the cells. Primary cell culture growth
was maintained in DMEM with 10% FCS. To confirm that the cells
were from osteoblastic lineage and so represented OS cultured
from the tumour sample, electron microscopy and alkaline
phophatase staining were performed. Osteocalcin levels were
measured in the supernatant of the flasks in which the cells were
cultured.
Histopathology
Osteosarcoma biopsies first underwent imprint staining for
alkaline phosphatase to rapidly confirm the diagnosis before
freezing for RNA preservation. Adjacent samples were histologi-
cally confirmed by Haematoxylin and Eosin staining. The extent of
necrosis within the postchemotherapy samples varied between 50
and 70%.
cDNA arrays
All experiments were performed on Human Genefilterst GF211
(/http://www.resgen. comS) nylon microarrays with 4324 known
human cDNA probes selected from Unigene. Osteosarcoma tissue
was dissected into approximately 0.5cm
3 pieces. Each piece was
placed into a sterile cryotube, immediately snap-frozen and stored
in liquid nitrogen until ready for RNA extraction. For RNA
extraction, frozen tumour tissue was placed in a guanidine–
thiocynate-containing buffer, RLT as supplied by RNeasy mini kit
(Qiagen
s Ltd, West Sussex, UK). Additional b-mercaptoethanol
(b-ME) was added as per the manufacturer’s instructions. The
specimen was initially homogenised, using a rotary star homo-
geniser then underwent further homogenisation using a Q1A
shredder (Qiagen
s Ltd, West Sussex UK). RNA extraction was
then followed as per the manufacturer’s protocol using an RNeasy
mini kit (Qiagen
s Ltd). For RNA extraction from cell lines and
primary cell cultures, the denaturing buffer was added directly to
the sterile tube containing the cell pellet. The sample was
homogenised using a Q1A shredder (Qiagen
s Ltd). RNA
extraction followed as per the manufacturer’s protocol using an
RNeasy mini kit (Qiagen
s Ltd). Integrity of total RNA was
confirmed by the presence of 28S and 18S ribosomal bands on 1%
agarose gels. The quantification and purity was assessed by
spectrophotometry. Single-stranded cDNA was synthesised as per
Research Genetics protocol (/http://www.resgen.comS). Total
RNA (5mg) was used to make each single probe. Duplicate probes
were made from one pool of RNA from each individual patient.
The probe was radiolabelled with
33PdCTP (ICN Radiochemicals,
Amersham, UK), then purified from unincorporated nucleotides
using a Biospin 6 column (Bio-Rad, Hertfordshine, UK #732–
6002). The radiolabelled probe was hybridised overnight to a
prehybridised nylon filter. Prehybridisation in a solution of
MicroHyb (Research Genetics, Huntsville, AL, USA) to which
Human Cot-1 (Human Cot-1 DNA, Life technologies now
Invitrogen Corporation, Daisley, UK # HYB125.GF) and poly dA
(Research Genetics Cat. #POLYA.GF, 1mgml
1, Huntsville, AL,
USA) were added was performed for at least 2h. Following
hybridisation with the radiolabelled probe, the filters were washed
using 0.5–1% concentrations of sodium dodecyl sulphate (SDS)
and 2X–0.5X SSC. The filters were exposed to a phosphor screen
for 48h and then scanned using a Cyclonet Packard Instrument
Company, Meridan, USA.
Data analysis
Image analysis was performed using Research Genetics Pathwayst
software. The expression values were then log scaled (base-2) and
the arrays median scaled to the array with the median overall
intensity. The quality of each array hybridisation was assessed by a
set of criteria including a s.d. and skew of the logged gene
expression values between 1–2 and 2–3 respectively. Nontypical
hybridisations were excluded from subsequent analysis. We used
duplicates for all arrays that had a correlation coefficient of 0.8 or
greater. Data generated from met-576, post-307, post-397 and loc-
R1 were not duplicate samples but met the remaining quality
control criteria. Average linkage hierarchical clustering of the log
transformed ratio values was performed using the program
Clustert after filtering the genes to remove nonvarying data
(SDo 0.5 of log transformed values) and presented using
Treeviewt (http:www.microarrays.org/software).
Immunohistochemistry
Immunohistochemistry (IHC) for Ezrin was achieved according to
the standard streptavidin–biotin-labelling method. Briefly, antigen
Table 1 Patient details
Id number Age Gender Histological subtype Type of sample % necrosis Time elapsed since cytotoxic chemotherapy
Loc-131 7 F Osteoblastic Diagnostic needle core biopsy 4 months
Pre-147 12 F Mixed differentiation Diagnostic needle core biopsy None
Pre-283 14 M Common Resection sample None
Pre-124 71 F Osteoblastic Resection sample None
Loc-181 14 F Common Resection sample None
Post-720 8 M Common Post chemotherapy resection o 90% necrosis 2–3 weeks
Post-125 16 F Fibroblastic Post chemotherapy resection o 90% necrosis 2–3 weeks
Post-876 22 M Common Post chemotherapy resection 70% necrosis 2–3 weeks
Post-139 16 F Osteoblastic Post chemotherapy resection o 90% necrosis 2–3 weeks
Post-397 18 M Osteoblastic Post chemotherapy resection o 90% necrosis 2–3 weeks
Post-307 23 M Common Post chemotherapy resection 50% necrosis 2–3 weeks
Post-111 13 F Osteoblastic Post chemotherapy resection o 90% necrosis 2–3 weeks
met-848 14 M Telangiectatic Metastatectomy 2–3 weeks
met-040 12 F Osteoblastic Metastatectomy 2–3 weeks
met-576 16 F Common Metastatectomy 14 months
met-c738 13 M Osteoblastic Metastatectomy 23 months
met-738 13 M Osteoblastic Metastatectomy 23 months
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high-pH antigen retrieval solution (DAKO, Cambridgeshire UK). A
rabbit polyclonal antibody (1:500 From ICR, London, UK
(Dr Richard Lamb) and an anti-rabbit ChemMate Detection Kit
(DAKO) were used as per the manufacturer’s instructions for
detection of the Ezrin protein. Two samples used corresponded to
the RNA samples used in the RT–PCR confirmatory study (post-
131 and met-738). Five other samples represent tissue used in the
microarray data set (pre-147, pre-283, post-125, post-139 and met-
740).
RESULTS AND DISCUSSION
Problems related to acquiring sufficient mRNA for meaningful
array analyses were exemplified in a recent study attempting such
analysis on fine needle aspiration (FNA) samples of breast cancer
tissue. Only 15% of FNA samples were suitable for array analysis
(Assersohn et al, 2002). Although the biopsies used in our study
represent more tissue than is present in FNA samples, the fact that
calcified bone tissue is part of these biopsies could potentially have
decreased the ability to extract sufficient quality RNA. In the
present study, all 22 tumour samples provided sufficient quality
total RNA for making radiolabelled cDNA probes. Subsequent
array data were derived from 16 of the 22 samples. The array data
from the outstanding six samples were excluded from further
analysis as they did not meet the statistical quality control criteria
(see Materials and Methods). The patient details of the remaining
16 samples are detailed in Table 1.
The most strongly expressed genes within the patient tumour
samples (above the 99th percentile of mean expression) contained
many known bone markers (see Table 2). In particular, Collagen-
1,alpha-2 and Matrix GLA are the major constituents of bone
matrix. Both of these were high in all samples demonstrating the
high osteoid content of all patient samples. Another highly
expressed gene Ezrin is reported for the first time in primary OS
samples (just below the 99th percentile). This gene is of particular
interest due to its previously reported association with metastasis
of an OS cell line in a murine model (Khanna et al, 2001).
Interestingly, while we found no marked difference in gene
expression between the different samples (see below) histopatho-
logical staining showed a distinctive membranous pattern in the
metastatic samples (Figure 1D), while primary and local recur-
rences showed both membrane and cytosolic staining (see Figure
1A–C). A similar finding was previously reported in uterine
endometrioid adenocarcinoma (Ohtani et al, 1999).
The data were then filtered to select approximately 1500 genes
that varied most between samples (s.d. of log 2 data 40.5). In the
subsequent hierarchical clustering of the samples (see Figure 2),
met-738 and the primary cell culture, we established from this
lesion (Met-c738), clustered tightly together. This suggests that for
array analysis, early passage primary cell culture, rather than laser
capture microdissection (LCM) (Simone et al, 2000), could be
useful to enrich for OS cells from a mixed tumour stromal
Table 2 Genes among the 99th most highly expressed on average in all
patient samples showed a distinct bone-like profile
Accession Gene name
AA076063 Caldesmon
AA397824 Dopachrome tautomerase
AA521431 Profilin
AA155913 Matrix Gla protein
AA872001 Annexin VI
AA490172 Collagen-I,a-2
AA411440 Ezrin
a
These genes were consistently high in all patients.
aExcepting Ezrin that lay just below
the 99th percentile of expression.
Figure 1 Immunohistochemical staining for Ezrin. (A) Prechemotherapy
diagnostic biopsy sample. (B) Postchemotherapy resection sample. (C)
Local recurrence diagnostic biopsy. (D) Metastatic sample. All pictures
40.
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technically possible to employ LCM on OS samples. However, it
was difficult to see any further pattern to the data from this
exploratory analysis.
An analysis of genes differentially expressed between primary
and metastatic samples is shown in Figure 3. (Po0.01). Among the
genes highly expressed in metastatic samples was the powerful
antioxidant xanthine dehydrogenase often associated with cellular
injury, and the genes associated with lymphocyte activation, CD73
and Interferon regulatory factor-4. The overexpression of genes in
the metastatic samples appeared higher than in primary. Both local
recurrence samples had a profile much more similar to primary
than metastatic disease.
Likewise, we also examined differences between samples either
cytotoxically treated immediately prior to resection Figure 4.
(Po0.01). Strikingly among the genes most highly expressed after
cytotoxic treatment were the myeloperoxidase gene associated with
intranuclear protection of DNA from damage by free radicals
(Borregaard & Cowland, 1997) and the thymine DNA glycosylase
that initiates repair of G/T and G/U mismatches after hydrolytic
deamination of 5-methylcytosine (Lindahl, 1982; Lindahl et al,
1982) Hsp-60 was also a highly expressed factor that may correlate
with apoptotic stress on the tumour cells.
We have demonstrated here that biopsies of bone tissue are
suitable for extraction of sufficient good quality RNA for GEM
analysis.
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Figure 3 Metastatic heatmap: genes highly expressed in metastatic
samples are shown (Po0.01). Note that both local recurrence samples
show a pattern of expression similar to the primary samples. Post,
postchemo primary; Pre, primary; Loc, local recurrence; Met, metastasis.
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Figure 4 Chemotherapy heatmap: genes highly expressed in che-
motherapy treated patients immediately prior to resection. All differences
were significant at Po0.01. Post, postchemo primary; Pre, primary; Loc,
local recurrence; Met, metastasis.
Expression profile of OS
P Leonard et al
2287
British Journal of Cancer (2003) 89(12), 2284–2288 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yPerou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack
JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A,
Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein
D (2000) Molecular portraits of human breast tumours. Nature 406:
747–752
Seker H, Odetayo MO, Petrovic D, Naguib RN, Bartoli C, Alasio L,
Lakshmi MS, Sherbet GV (2002) Assessment of nodal involvement and
survival analysis in breast cancer patients using image cytometric data:
statistical, neural network and fuzzy approaches. Anticancer Res 22:
433–438
Selaru FM, Xu Y, Yin J, Zou T, Liu TC, Mori Y, Abraham JM, Sato F, Wang
S, Twigg C, Olaru A, Shustova V, Leytin A, Hytiroglou P, Shibata D,
Harpaz N, Meltzer SJ (2002) Artificial neural networks distinguish
among subtypes of neoplastic colorectal lesions. Gastroenterology 122:
606–613
Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC,
Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA,
Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster
JC, Golub TR (2002) Diffuse large B-cell lymphoma outcome prediction
by gene-expression profiling and supervised machine learning. Nat Med
8: 68–74
Simone NL, Remaley AT, Charboneau L, Petricoin EF, Glickman JW,
Emmert-Buck MR, Fleisher TA, Liotta LA (2000) Sensitive immunoassay
of tissue cell proteins procured by laser capture microdissection. Am J
Pathol 156: 445–452
Stiller CA, Bunch KJ (1990) Trends in survival for childhood cancer in
Britain diagnosed 1971–85. Br J Cancer 62: 806–815
Whelan JS, Cannon SR (2002) Osteosarcoma. In Oxford Textbook of
Oncology, Souhami RL, Tannock I, Hohenberger P, Horiot J-C (eds) pp
2553–2570. Oxford: Oxford University Press
Expression profile of OS
P Leonard et al
2288
British Journal of Cancer (2003) 89(12), 2284–2288 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y